GlobeNewsWire
07 Jul 2026, 11:42 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
Clearmind Medicine successfully completed a formulation feasibility study for the intranasal delivery of its lead candidate, MEAI. — Successful feasibility studies reduce technical risk for a new delivery method, potentially expanding the drug's marketability and patient adherence.
+0.40The company is pursuing intranasal administration specifically for the treatment of alcohol use disorder (AUD). — Targeting a high-unmet-need market like AUD provides a clear commercial pathway, though this is an early-stage development update.
+0.20Which stocks this story touches
The company reported successful formulation feasibility studies for a new intranasal delivery route of its lead therapeutic candidate MEAI.
Continue reading
6 related stories
Top 3 movers · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
1h ago
